FICB combined with dexmedetomidine reduces pain, inflammatory markers and improves sleep after THA
J Orthop Surg Res. 2020; 15: 42.One hundred and nineteen elderly patients with hip fractures scheduled for a total hip arthroplasty were randomized to receive a fascia iliaca compartment blockade (FICB) and dexmedetomidine (DEX), FICB only, or control for the management of pain and inflammation. Outcomes of interest included inflammatory markers, pain at rest and during motion on a Visual Analog Scale (VAS), and sleep quality as measured with the Pittsburgh Sleep Quality Index. Results revealed all outcomes to be significantly in favour of the FICB+DEX group. No significant differences in adverse events were observed among the three groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
